Member Info for Adastra

Totally agree. I bought in on the basis of brand awareness for Hotter and the resilient and sizeable demographic group on it's database. I like the opportunity to cross-sell once Hotter transitions to Unbound and the low-cost low-cost drop-ship model being employed. July 28th sees it launch and it could really fly. Paul Scott gave a decent synopsis. What I don't like is the way the price has been walked down to get it away at such a discount. The directors could have been more proactive in their funding options but Instos will only come on board as the company shares in issue expands. The end game is probably to sell to a bigger player addressing this demographic group e.g. Saga but I can see the logic behind chasing the growing number of active over 55's.

Only a week till the huge 'drop-ship' multiple platform launch.......low risk/low cost/big upside potential. 23p is a steal prior to the publicity that will accompany the Hotter-led launch.
Do the research, tuck some away.
https://www.theindustry.fashion/podcasts/ian-watson-ceo-unbound-group-parent-co-of-hotter-shoes/

The real clincher for me are that there has been consistent and committed sharebuying by directors at prices significantly above today. Plus the nil paid share options announced on March 21st only vest when EARNINGS not share price are virtually equal to the current share price! Quote --
Earnings Per Share in the Year to January 2025 (weighting 50%): Vesting will start from a threshold of 18.60 pence per share, with maximum vesting at 22.74 pence per share
---- looks very fair starting point to ramp up to that in 2025.....

Like the current temperature, Unbound and it's Hotter Shoes new online platform will set the share price on fire......soon.....very soon. Launch date for the multibrand platform...July 28th...one week to go. Hot stock in the making...all imo so dye.

The launch of the new multibrand platform on July 28th should provide a welcome lift to the shares which are significantly oversold at present. Recent strong director buys indicate their commitment to the Hotter brand and the way forward. All indicators show trading in line and with a new Nomad we should see decent analyst updates. Good time to get on board if you've DYOR.

Sitting duck bar none at this level....... Deepak, for whatever reason, did S&N no favours by selling his 'Siemens Healthineers equivalence' shares. The subsequent and unjustified fall in share price and hence MCap has now well and truly put S&N in the takeover crosshairs. I'm certain that J&J will have looked again but it's in the middle of a company restructure. That doesn't preclude it, just complicates it. To be quite honest, S&N fits perfectly into the J&J scenario in that the company itself splits easily into medical devices and surgical dressings. That fact also plays alluringly into the private equity arena. This is a resilient recession-proof company. Too much emphasis is being placed on any NHS woes but over 50% of revenue is Stateside with ROW filling the gaps. The huge new Malaysian facility is up and running with a similar SOTA one in the UK transitioned for 2024 with UK govt fund and company cash allocated. Big backlogs for elective surgery worldwide sees secure income streams and a solid horizon. Huge barriers to entry as reputation and provenance are drivers - S&N has 150yrs of both. This is the best UK steal since Cadbury.......Sitting tight whatever. Solid.

There has to be a huge gap-jump on the cards here. How long can the obvious attractions of this share stay at complete odds with its current value? Something has to give.... Private equity and US players must be all over this at the moment. Frustrating, but should benefit those of us long players in the very near future. July 28th for interims and update may provide more than solid figures as it initiates a little action....we shall see. Just too darned low for such a solid company in the right places at the right time. Transformational.

Cable below 1.2, earns and declares in $, 50%+ business generated in USA, 2 new $100m SOTA manufacturing facilities (one just opened in Malaysia, one in 2024 in UK) and huge tax breaks available for US suitor...... sitting duck. Needs to get MCap up to keep independence.

Three weeks till we get the interims which should give a decent update on progress with news on the new Malaysian facility and feedback regarding the expansion of ASC work in the States. The USA now accounts for over 50% of S&N business and is growing nicely. The new robotic cementless knee system has undergone first orthopaedic use so good to see practitioner response. It's difficult to keep abreast of all the cutting edge tech going on here but the need to relocate to much bigger SOTA premises near Hull as recently agreed is a good indicator of company health. The nadir of the S&N share price and the peak of virulent Covid appears to be behind us at last. The t/u should verify that and give a good indication that progress is escalating within the business worldwide.

Nice to see a decent write up on prospects from Paul Scott after s Q+A session with management. Solid with considerable potential upside given imminent release of new platform.

S&N is now at its most vulnerable to an unsolicited approach in 30 years imo. Cable rate, prospects, unequalled provenance and practitioner trust, massive tax breaks for US major, virtually recession-proof......massively undervalued and very very exposed with opening of Malaysian super hub.

https://m.marketscreener.com/quote/stock/SMITH-NEPHEW-PLC-9590181/news/Smith-Nephew-Says-First-Robotic-Assisted-Surgery-Performed-Using-Its-Legion-Conceloc-Knee-Implants-40868617/

https://www.marketscreener.com/quote/stock/SMITH-NEPHEW-PLC-9590181/news/Smith-Nephew-Nephew-opens-world-class-manufacturing-facility-in-Malaysia-to-support-its-orthopa-40841504/

The exceptional provenance and unbroken dividends combined with cutting-edge world-class products leads me to ask a question that has niggled me for a long time. Virtually all FTSE 350 companies and above regularly RNS major events in order to inform investors of progress and encourage investment. Smith and Nephew is singularly the exception to this. If you list all the RNS announcements for the company there is virtually NO information on which a potential institutional or private investor can make an informed decision; they have to visit the website. Added to that is the fact that most investment managers and private individuals access information at 7.00 am UK time. Most RNS statements are not presented at that time as they are issued after the UK market has closed and are not 'served up' in the wider morning digest

Agree, decent RNS with lots of near term events to support and increase interest and price. I just really wish that management would reiterate their guidance and expectations in figures rather than the eternal cover all ""continues to trade in line with the Board's expectations for the year ending 5 February 2023."" That really irritates PI's like myself as you have to go on a proverbial bear hunt to find them.....wake up AIM listers....

Should get decent feedback and good interims with news of new SOTA Malaysian manufacturing and distribution facility/hub due to open anytime. This is so behind the curve in its price.....potential bidders in the USA must be blind....their loss...!

Trading well under NAV if all is good with results as telegraphed on last t/u this should rapidly gap jump and rerate from here.

28.04 sell 28.90 buy so many more buys than sells in anticipation of annual results due anytime.... tomorrow? Good sales and the imminent launch of new platform in July mean that these buy prices will be history very soon. Intrinsic value now considerably above current MCap.

** RBC adds SN's business is sufficiently undervalued and current strategy sufficiently convincing that it is "better to risk being too early than too late"

https://fashionunited.uk/news/business/unbound-group-to-launch-multi-brand-retail-platform/2022052563265